Exelixis, Inc. (Nasdaq: EXEL) and Natera (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, today announced their collaboration on the planned Exelixis-sponsored STELLAR-316 ...
Exelixis (EXEL) stock falls as Bank of America downgrades the company to Underperform, citing valuation and no near-term ...
Investing.com -- Exelixis Inc (NASDAQ:EXEL) stock rose 3.8% and Natera Inc (NASDAQ:NTRA) shares gained 1.6% Wednesday after the companies announced a collaboration on a pivotal phase 3 trial for ...
Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will provide a corporate overview at the J.P. Morgan 2026 ...
TipRanks on MSN
Exelixis downgraded to underperform from neutral at BofA
BofA downgraded Exelixis (EXEL) to Underperform from Neutral with a price target of $41, down from $43, citing valuation and limited high-impact ...
Exelixis is an expert in developing cancer drugs, as evidenced by its biggest growth driver, Cabometyx. The company has several pipeline candidates, some of which seek to address large unmet needs.
Exelixis is making money moves, penning two new deals for a total of $100 million upfront to earn the chance to add several new oncology assets to its pipeline. The genomics-based biotech is handing ...
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter of 2023 and provided an update on progress toward achieving key corporate ...
Exelixis, having already reported one surprising flop over the summer with its combo of Cabometyx and Roche’s Tecentriq in liver cancer, is hoping for a different outcome in difficult-to-treat ...
Zacks Investment Research on MSN
Why Exelixis (EXEL) is a top momentum stock for the long term
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) and Aurigene Discovery Technologies Limited (Aurigene) today disclosed new preclinical data showing that AUR102 has potent anti-tumor ...
The pharmaceutical company is moving beyond its longtime reliance on a single cancer drug, but what will those changes mean for shareholders? Michelin, the tire company, makes tires. There is no Wall ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback